Harvard Bioscience (HBIO) Competitors

$6.63 +0.23 (+3.59%)

Closing price 04:00 PM Eastern

Extended Trading

$6.62 -0.01 (-0.23%)

As of 05:38 PM Eastern

HBIO vs. LMNX, TMO, A, WAT, and MTD

Should you be buying Harvard Bioscience stock or one of its competitors? The main competitors of Harvard Bioscience include Defiance Daily Target 2X Long LMND ETF (LMNX), Thermo Fisher Scientific (TMO), Agilent Technologies (A), Waters (WAT), and Mettler-Toledo International (MTD). These companies are all part of the "life sciences tools & services" industry.

How does Harvard Bioscience compare to Defiance Daily Target 2X Long LMND ETF?

Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap life sciences tools & services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

: In the previous week, Defiance Daily Target 2X Long LMND ETF had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 3 mentions for Defiance Daily Target 2X Long LMND ETF and 1 mentions for Harvard Bioscience. Defiance Daily Target 2X Long LMND ETF's average media sentiment score of 0.00 equaled Harvard Bioscience'saverage media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Defiance Daily Target 2X Long LMND ETF
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Harvard Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Defiance Daily Target 2X Long LMND ETF has a net margin of 5.39% compared to Harvard Bioscience's net margin of -65.51%. Defiance Daily Target 2X Long LMND ETF's return on equity of 4.66% beat Harvard Bioscience's return on equity.
Company Net Margins Return on Equity Return on Assets
Defiance Daily Target 2X Long LMND ETF 5.39% 4.66% 2.91%
Harvard Bioscience -65.51% -19.54% -3.59%
: Harvard Bioscience has a consensus target price of $6.00, suggesting a potential downside of 9.50%. Given Harvard Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Harvard Bioscience is more favorable than Defiance Daily Target 2X Long LMND ETF.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Defiance Daily Target 2X Long LMND ETF
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Harvard Bioscience
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Defiance Daily Target 2X Long LMND ETF has a beta of -10.61, suggesting that its share price is 1,161% less volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.
: 87.8% of Defiance Daily Target 2X Long LMND ETF shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 6.6% of Defiance Daily Target 2X Long LMND ETF shares are owned by insiders. Comparatively, 20.3% of Harvard Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
: Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Defiance Daily Target 2X Long LMND ETF, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Defiance Daily Target 2X Long LMND ETF $437.66M 0.01 $15.17M $0.51 27.31
Harvard Bioscience $86.55M 0.35 -$56.70M -$12.80 N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Defiance Daily Target 2X Long LMND ETF	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Defiance Daily Target 2X Long LMND ETF	5.39%	4.66%	2.91%
Harvard Bioscience	-65.51%	-19.54%	-3.59%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Defiance Daily Target 2X Long LMND ETF	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Defiance Daily Target 2X Long LMND ETF	$437.66M	0.01	$15.17M	$0.51	27.31
Harvard Bioscience	$86.55M	0.35	-$56.70M	-$12.80	N/A

Summary

Defiance Daily Target 2X Long LMND ETF beats Harvard Bioscience on 9 of the 15 factors compared between the two stocks.

How does Harvard Bioscience compare to Thermo Fisher Scientific?

Harvard Bioscience (NASDAQ:HBIO) and Thermo Fisher Scientific (NYSE:TMO) are both life sciences tools & services companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

: In the previous week, Thermo Fisher Scientific had 31 more articles in the media than Harvard Bioscience. MarketBeat recorded 32 mentions for Thermo Fisher Scientific and 1 mentions for Harvard Bioscience. Thermo Fisher Scientific's average media sentiment score of 1.15 beat Harvard Bioscience's score of 0.00 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Harvard Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Thermo Fisher Scientific
24 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
: Thermo Fisher Scientific has a net margin of 15.15% compared to Harvard Bioscience's net margin of -65.51%. Thermo Fisher Scientific's return on equity of 16.86% beat Harvard Bioscience's return on equity.
Company Net Margins Return on Equity Return on Assets
Harvard Bioscience -65.51% -19.54% -3.59%
Thermo Fisher Scientific 15.15% 16.86% 8.15%
: Harvard Bioscience currently has a consensus target price of $6.00, indicating a potential downside of 9.50%. Thermo Fisher Scientific has a consensus target price of $623.05, indicating a potential upside of 33.49%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Harvard Bioscience.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harvard Bioscience
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Thermo Fisher Scientific
0 Sell rating(s)

2 Hold rating(s)

19 Buy rating(s)

2 Strong Buy rating(s)
3.00
: Harvard Bioscience has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
: 80.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are held by institutional investors. 20.3% of Harvard Bioscience shares are held by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Thermo Fisher Scientific has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Harvard Bioscience $86.55M 0.35 -$56.70M -$12.80 N/A
Thermo Fisher Scientific $44.56B 3.89 $6.70B $18.19 25.66

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Thermo Fisher Scientific	24 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-65.51%	-19.54%	-3.59%
Thermo Fisher Scientific	15.15%	16.86%	8.15%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Thermo Fisher Scientific	0 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$86.55M	0.35	-$56.70M	-$12.80	N/A
Thermo Fisher Scientific	$44.56B	3.89	$6.70B	$18.19	25.66

Summary

Thermo Fisher Scientific beats Harvard Bioscience on 15 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Harvard Bioscience (NASDAQ:HBIO) are both life sciences tools & services companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

: 80.9% of Harvard Bioscience shares are owned by institutional investors. 20.3% of Harvard Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: Agilent Technologies has a net margin of 18.26% compared to Harvard Bioscience's net margin of -65.51%. Agilent Technologies' return on equity of 24.49% beat Harvard Bioscience's return on equity.
Company Net Margins Return on Equity Return on Assets
Agilent Technologies 18.26% 24.49% 12.83%
Harvard Bioscience -65.51% -19.54% -3.59%
: Agilent Technologies presently has a consensus target price of $163.71, indicating a potential upside of 39.27%. Harvard Bioscience has a consensus target price of $6.00, indicating a potential downside of 9.50%. Given Agilent Technologies' stronger consensus rating and higher possible upside, equities research analysts plainly believe Agilent Technologies is more favorable than Harvard Bioscience.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agilent Technologies
0 Sell rating(s)
2 Hold rating(s)

11 Buy rating(s)

2 Strong Buy rating(s)
3.00
Harvard Bioscience
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Agilent Technologies has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agilent Technologies $6.95B 4.78 $1.30B $4.53 25.95
Harvard Bioscience $86.55M 0.35 -$56.70M -$12.80 N/A
: Agilent Technologies has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.
: In the previous week, Agilent Technologies had 10 more articles in the media than Harvard Bioscience. MarketBeat recorded 11 mentions for Agilent Technologies and 1 mentions for Harvard Bioscience. Agilent Technologies' average media sentiment score of 0.97 beat Harvard Bioscience's score of 0.00 indicating that Agilent Technologies is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Agilent Technologies
6 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Harvard Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	18.26%	24.49%	12.83%
Harvard Bioscience	-65.51%	-19.54%	-3.59%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	4.78	$1.30B	$4.53	25.95
Harvard Bioscience	$86.55M	0.35	-$56.70M	-$12.80	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Agilent Technologies beats Harvard Bioscience on 14 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Waters?

Waters (NYSE:WAT) and Harvard Bioscience (NASDAQ:HBIO) are both life sciences tools & services companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

: In the previous week, Waters had 25 more articles in the media than Harvard Bioscience. MarketBeat recorded 26 mentions for Waters and 1 mentions for Harvard Bioscience. Waters' average media sentiment score of 0.78 beat Harvard Bioscience's score of 0.00 indicating that Waters is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Waters
12 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Harvard Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Waters has a net margin of 20.30% compared to Harvard Bioscience's net margin of -65.51%. Waters' return on equity of 34.79% beat Harvard Bioscience's return on equity.
Company Net Margins Return on Equity Return on Assets
Waters 20.30% 34.79% 16.29%
Harvard Bioscience -65.51% -19.54% -3.59%
: 94.0% of Waters shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 0.3% of Waters shares are owned by company insiders. Comparatively, 20.3% of Harvard Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Waters has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Waters $3.17B 10.62 $642.63M $10.77 31.81
Harvard Bioscience $86.55M 0.35 -$56.70M -$12.80 N/A
: Waters has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500.
: Waters presently has a consensus target price of $387.53, indicating a potential upside of 13.12%. Harvard Bioscience has a consensus target price of $6.00, indicating a potential downside of 9.50%. Given Waters' stronger consensus rating and higher probable upside, analysts plainly believe Waters is more favorable than Harvard Bioscience.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Waters
0 Sell rating(s)
8 Hold rating(s)

9 Buy rating(s)

3 Strong Buy rating(s)
2.75
Harvard Bioscience
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Waters	12 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Waters	20.30%	34.79%	16.29%
Harvard Bioscience	-65.51%	-19.54%	-3.59%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Waters	$3.17B	10.62	$642.63M	$10.77	31.81
Harvard Bioscience	$86.55M	0.35	-$56.70M	-$12.80	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Waters	0 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.75
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Waters beats Harvard Bioscience on 15 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Mettler-Toledo International?

Harvard Bioscience (NASDAQ:HBIO) and Mettler-Toledo International (NYSE:MTD) are both life sciences tools & services companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

: Harvard Bioscience presently has a consensus target price of $6.00, indicating a potential downside of 9.50%. Mettler-Toledo International has a consensus target price of $1,459.58, indicating a potential upside of 12.09%. Given Mettler-Toledo International's stronger consensus rating and higher probable upside, analysts clearly believe Mettler-Toledo International is more favorable than Harvard Bioscience.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harvard Bioscience
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Mettler-Toledo International
0 Sell rating(s)

6 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.54
: In the previous week, Mettler-Toledo International had 10 more articles in the media than Harvard Bioscience. MarketBeat recorded 11 mentions for Mettler-Toledo International and 1 mentions for Harvard Bioscience. Mettler-Toledo International's average media sentiment score of 1.22 beat Harvard Bioscience's score of 0.00 indicating that Mettler-Toledo International is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Harvard Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Mettler-Toledo International
8 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Mettler-Toledo International has a net margin of 21.59% compared to Harvard Bioscience's net margin of -65.51%. Harvard Bioscience's return on equity of -19.54% beat Mettler-Toledo International's return on equity.
Company Net Margins Return on Equity Return on Assets
Harvard Bioscience -65.51% -19.54% -3.59%
Mettler-Toledo International 21.59% -495.07% 25.47%
: Harvard Bioscience has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.
: Mettler-Toledo International has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Harvard Bioscience $86.55M 0.35 -$56.70M -$12.80 N/A
Mettler-Toledo International $4.03B 6.55 $869.19M $42.12 30.92
: 80.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are held by institutional investors. 20.3% of Harvard Bioscience shares are held by company insiders. Comparatively, 0.7% of Mettler-Toledo International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mettler-Toledo International	0 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.54

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mettler-Toledo International	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-65.51%	-19.54%	-3.59%
Mettler-Toledo International	21.59%	-495.07%	25.47%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$86.55M	0.35	-$56.70M	-$12.80	N/A
Mettler-Toledo International	$4.03B	6.55	$869.19M	$42.12	30.92

Summary

Mettler-Toledo International beats Harvard Bioscience on 13 of the 16 factors compared between the two stocks.

Get Harvard Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HBIO vs. The Competition

Export

Metric	Harvard Bioscience	INSTRU Industry	Computer Sector	NASDAQ Exchange
Market Cap	$28.86M	$955.53M	$37.08B	$11.77B
Dividend Yield	N/A	0.55%	3.20%	5.26%
P/E Ratio	-0.52	4.99	154.78	23.23
Price / Sales	0.35	1.34	620.65	75.49
Price / Cash	0.55	5.49	45.74	53.90
Price / Book	2.16	2.90	9.29	6.69
Net Income	-$56.70M	-$9.28M	$1.03B	$332.64M
7 Day Performance	2.79%	8.75%	4.88%	2.01%
1 Month Performance	27.50%	13.88%	14.33%	9.19%
1 Year Performance	100.97%	14.12%	168.78%	39.59%

Harvard Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HBIO Harvard Bioscience	1.0604 of 5 stars	$6.63 +3.6%	$6.00 -9.5%	N/A	$28.86M	$86.55M	N/A	490	News Coverage Upcoming Earnings
LMNX Defiance Daily Target 2X Long LMND ETF	N/A	$18.37 -3.3%	N/A	N/A	$5.88M	$437.66M	36.02	1,325	News Coverage
TMO Thermo Fisher Scientific	4.918 of 5 stars	$469.51 +0.3%	$623.05 +32.7%	N/A	$174.29B	$45.20B	25.78	125,000	Positive News
A Agilent Technologies	4.8912 of 5 stars	$115.15 -0.4%	$163.71 +42.2%	N/A	$32.53B	$6.95B	25.41	18,100	Gap Up
WAT Waters	3.7781 of 5 stars	$300.05 +0.1%	$387.53 +29.2%	N/A	$29.40B	$3.17B	27.81	7,900	Trending News Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HBIO) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harvard Bioscience (HBIO) Competitors

HBIO vs. LMNX, TMO, A, WAT, and MTD

How does Harvard Bioscience compare to Defiance Daily Target 2X Long LMND ETF?

Summary

How does Harvard Bioscience compare to Thermo Fisher Scientific?

Summary

How does Harvard Bioscience compare to Agilent Technologies?

Summary

How does Harvard Bioscience compare to Waters?

Summary

How does Harvard Bioscience compare to Mettler-Toledo International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harvard Bioscience (HBIO) Competitors

HBIO vs. LMNX, TMO, A, WAT, and MTD

How does Harvard Bioscience compare to Defiance Daily Target 2X Long LMND ETF?

Summary

How does Harvard Bioscience compare to Thermo Fisher Scientific?

Summary

How does Harvard Bioscience compare to Agilent Technologies?

Summary

How does Harvard Bioscience compare to Waters?

Summary

How does Harvard Bioscience compare to Mettler-Toledo International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools